Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(fenofibrate)
3,629 results
  • A Protective Effect of PPARα in Endothelial Progenitor Cells Through Regulating Metabolism. [Journal Article]
    Diabetes 2019Shao Y, Chen J, … Ma JX
  • Deficiency of endothelial progenitor cells, including endothelial colony-forming cells (ECFC) and circulating angiogenic cells (CAC), plays an important role in retinal vascular degeneration in diabetic retinopathy (DR). Fenofibrate, an agonist of peroxisome proliferator-activated receptor-α (PPARα), has shown therapeutic effects on DR in both patients and diabetic animal models. However, the fun…
  • Macroprolactinaemia modulates cardiometabolic effects of fenofibrate in men with atherogenic dyslipidaemia: A pilot study. [Journal Article]
    J Clin Pharm Ther 2019Krysiak R, Kowalcze K, Okopień B
  • CONCLUSIONS: Men with elevated levels of big-big prolactin were characterized by higher levels of hsCRP and fibrinogen and lower levels of 25-hydroxyvitamin D as well as decreased insulin sensitivity than subjects with prolactin levels within the reference range. In men without macroprolactinaemia, fenofibrate decreased circulating levels of total and LDL cholesterol, triglycerides, uric acid, hsCRP and fibrinogen, and increased concentrations of HDL cholesterol, homocysteine and 25-hydroxyvitamin D, as well as improved insulin sensitivity. In subjects with macroprolactinaemia, fenofibrate action was limited to the changes in HDL cholesterol, triglycerides, hsCRP and homocysteine. With the exception of homocysteine, cardiometabolic effects of fenofibrate were stronger in subjects without than in subjects with elevated levels of big-big prolactin.The results of the study indicate that macroprolactinaemia exerts a negative impact on cardiometabolic effects of fenofibrate.
New Search Next